US marketing to get tough for Ranbaxy Laboratories – The Financial Express
Ranbaxy Laboratories is, however, confident that it will continue bringing “safe, effective and quality medicines to market”. For the January-March 2013 quarter, US sales stood at R595 crore. During the quarter, the company filed three ANDAs for the US …
See all stories on this topic »
Netflix Arrested Development Viral Marketing Campaign – Peter …
Would you like to see the “The Acting Styles of Dr. Tobias Funke”? Yes, you would.AllThingsD
See all stories on this topic »
Can Marketing Your Social Impact Harm Your Social Impact?
This marketing dilemma is one that many social entrepreneurs face. Should they market the stories behind their beneficiaries or employees and share facts about the livelihoods of those being helped by the purchase of the products, or let the products …
See all stories on this topic »
Popular Questions
Why was US marketing getting tough for Ranbaxy Laboratories according to The Financial Express?
US marketing was becoming more difficult for Ranbaxy Laboratories because the company faced regulatory scrutiny in its largest overseas market. Concerns about manufacturing standards, product approvals, and compliance could delay launches and restrict access to the US market. These issues threatened both sales growth and the company’s reputation among regulators and customers.
How could stricter US regulations affect Ranbaxy Laboratories’ marketing strategy?
Stricter US regulations could force Ranbaxy Laboratories to place greater emphasis on compliance before promoting or launching medicines. The company might need to invest in quality controls, facility improvements, documentation, and closer communication with regulators. Marketing plans would also have to account for approval delays and possible limits on product distribution.
What role did regulatory concerns play in making US marketing tough for Ranbaxy Laboratories?
Regulatory concerns were central to the pressure facing Ranbaxy Laboratories in the United States. Questions about manufacturing and product-quality practices could lead to inspections, import restrictions, or delays in approvals. Until those concerns were resolved, the company’s ability to compete effectively in the US generic-drug market could remain limited.
What should Ranbaxy Laboratories do when US marketing gets tough?
Ranbaxy Laboratories would need to strengthen manufacturing compliance and address regulators’ concerns with clear corrective actions. It should maintain accurate quality records, improve oversight at affected facilities, and communicate progress transparently. Resolving those operational issues would be more important than increasing promotional activity in the US market.